Nutritional Formulation for Angelman Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-01

Study Completion Date

2020-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Low carbohydrate diets such as the ketogenic (KD) and low glycemic index (LGIT) diets have been shown to be effective in treating drug resistant seizures in children with Angelman syndrome (AS). The investigators hypothesize that consuming a fat based nutritional formulation with an exogenous ketone throughout the day will produce urinary ketosis in children consuming both low and high carbohydrate diets, depending upon dietary background. The nutritional formulation will provide fuel substrates that push metabolism away from carbohydrates and towards fat utilization. This research is being done to assess the safety and tolerability of a nutritional formulation for use in dietary interventions in AS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ketogenic Diet for Child Epilepsy and Seizure Control

NCT00004729

Epilepsy Seizures Lennox-Gastaut Syndrome

COMPLETED NA

Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial

NCT02176096

Glycogen Storage Disorder Type 1 Hypoglycemia Cornstarch +1 more

COMPLETED NA

Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

NCT02216500

Seizures

RECRUITING NA

Ketogenic Diet for Refractory Status Epilepticus

NCT01796574

Status Epilepticus Seizure Epilepsy +2 more

COMPLETED NA

Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy

NCT00552526

Epilepsy Mental Retardation

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An evaluation of the safety and tolerability of a nutritional formulation in Angelman syndrome in children ages 4-11 years.

Study is conducted over 16 weeks:

2 week baseline period - Patient continues on current dietary regimen they were on before joining the study (standard, ketogenic, or LGIT).

4 week intervention period - Patient consumes either placebo or nutritional formulation for 4 weeks, maintaining their current diet.

4 week washout period - Patient continues on current dietary regimen without consuming any study formulations.

4 week intervention period - Patient consumes either placebo or nutritional formulation for 4 weeks (crossover), maintaining their current diet.

2 week washout period - Patient continues on current dietary regimen without consuming any study formulations.

Follow-up phone call to be conducted by study personnel during this time.

Data is captured by the investigator during baseline, intervention, and washout periods, and by the parent/caregiver daily throughout the protocol using apps loaded on a provided tablet.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angelman Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

The study design for this nutritional intervention protocol is a randomized, double blind, placebo controlled crossover study. Each patient will receive both nutritional formulation and placebo formulation, with a washout period between each arm. The dietary backgrounds will differ among patients. Acceptable diets include three basic diets: ketogenic diet (i.e. conventional 4:1 or 3:1, modified Atkins), low glycemic index diet (LGIT), and standard American diet (regular diet).

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational

Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.

Group Type EXPERIMENTAL

Nutritional Formulation Containing Exogenous Ketones

Intervention Type DIETARY_SUPPLEMENT

A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.

Placebo

Subjects assigned to this arm will receive the Placebo Formulation.

Group Type PLACEBO_COMPARATOR

Placebo Formulation

Intervention Type DIETARY_SUPPLEMENT

A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nutritional Formulation Containing Exogenous Ketones

A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.

Intervention Type DIETARY_SUPPLEMENT

Placebo Formulation

A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female
* 4-11 years of age
* Diagnosed with Angelman syndrome with prior lab report indicating genetic diagnosis
* Currently on a LGIT, KD, or standard diet consistently for at least three months
* Motivated to maintain the LGIT or KD for at least the duration of the trial period, as applicable
* Written informed consent from patient and/or parent/caregiver
* Willing to drink provided formulations, or to eat them mixed with food
* Daytime toilet trained, or parents willing to use cotton balls in diapers to sample urine
* Willing to test urine daily
* Willing to comply with protocol examinations, including EEG, ERP, and venipuncture
* Ambulatory, willing to perform gait tracking

Exclusion Criteria

* Being pregnant or planning pregnancy
* Requiring parenteral nutrition
* Major hepatic or renal dysfunction
* History of a diagnosis of diabetes
* Participation in other clinical intervention studies within 1 month prior to entry of this study
* Allergy to any of the study product ingredients
* Investigator concern around willingness/ability of patient or parent/caregiver to comply with protocol requirements
* Any contraindications for the use of the ketogenic or low carbohydrate diets
* Significantly underweight (Body Mass Index \<18.5)
* Unwilling to drink provided formulations, or to consume formulation mixed with food
* Not ambulatory, or unwilling to perform gait tracking
* Not daytime toilet trained, or parents unwilling to use cotton balls in diapers to sample urine
* Unwilling to test urine daily

Minimum Eligible Age

4 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No